logo-loader
viewhVIVO PLC

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands service offerings

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year.

The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June 30, up £1mln year-on-year, or 20%.

''There's a lot of demand, a lot of interest in what we do and we've also expanded our service offering ... which means we've got a broader base now of potential clients that could work with us''.

''The pipeline looks strong, the cost base has been brought down to  a level where it's an acceptable level for the sort of revenues we expect to generate''.

Quick facts: hVIVO PLC

Price: 15.9 GBX

LSE:HVO
Market: LSE
Market Cap: £13.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: hVIVO’s mosquito vaccine moves into the clinic

Headlines from the Proactive Investors UK newsroom.  Clinical services group hVIVO’s (LON:HVO) experimental vaccine AGS-v PLUS is to undergo a phase 1 safety trial at the University of Maryland school of medicine. The vaccine is designed to protect against mosquito-borne diseases such as...

on 31/7/19

2 min read